Sionna Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio
Sionna Therapeutics, Inc. Common Stock cash flow-to-debt ratio. Sionna Therapeutics, Inc. Common Stock (SION) has a Cash Flow-to-Debt Ratio of -0.87x as of December 2025, meaning its operating cash flow of $-16.63 Million could theoretically repay -1% of its total liabilities ($19.12 Million) in one year. See financial agility of Sionna Therapeutics, Inc. Common Stock to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Sionna Therapeutics, Inc. Common Stock (2022–2025)
Cash flow-to-debt ratio of Sionna Therapeutics, Inc. Common Stock from 2022 to 2025. Historical debt coverage capacity for Sionna Therapeutics, Inc. Common Stock across 4 annual periods. Also explore Sionna Therapeutics, Inc. Common Stock equity growth rate to track the company's year-over-year net asset growth rate.
Sionna Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2022–2025)
Sionna Therapeutics, Inc. Common Stock cash flow-to-debt ratio by year from 2022 to 2025. Year-by-year debt coverage analysis for Sionna Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see Sionna Therapeutics, Inc. Common Stock cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.47x | $-66.30 Million | $19.12 Million | ▼ -2195.5% |
| 2024 | -0.15x | $-52.79 Million | $349.46 Million | ▲ +42.3% |
| 2023 | -0.26x | $-43.70 Million | $166.83 Million | ▼ -14.2% |
| 2022 | -0.23x | $-36.07 Million | $157.29 Million | — |